Analyst Profile

Followed by 46 followers
.
Gary Nachman

Gary Nachman

BMO Capital
Wall Street Analyst
#7,907 out of 8,141 Wall Street Analysts
#23,574 out of 24,284 experts

Success Rate

41%
132 out of 322 transactions made a profit

Average Return

-9.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Gary Nachman's trades since 2010 and holding each position for 1 Year would result in 40.99% of your transactions generating a profit, with an average return of -9.8% per rating.

Stock Rating Distribution

589Ratings
63.33% Buy
35.31% Hold
1.36% Sell
Distribution of Gary Nachman's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
SAGE Therapeutics, Inc. (US)
(SAGE)
Rating:Buy
Date:Jan 29, 2017 - Jan 29, 2018
Return:+288.40%
The most profitable rating made by Gary Nachman

Gary Nachman's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
SCMP
Sucampo Pharmaceuticals
Mar 16, 2010
Buy
Reiterated
1Ratings
100%
+5.90%
QCOR
Questcor
Sep 17, 2013
Hold
Initiated
1Ratings
0.00%
KYTH
Kythera
Sep 17, 2013
Hold
Initiated
1Ratings
0.00%
Amarin
Oct 09, 2013
Hold
Reiterated
$6.80
(496.49% Upside)
2Ratings
0.00%
AUXL
Auxilium
Sep 18, 2014
Hold
Downgraded
2Ratings
100%
+68.90%
SLXP
Salix
Dec 18, 2014
Hold
Assigned
4Ratings
0.00%
~ANAC
Anacor Pharmaceuticals
Jul 21, 2015
Buy
Upgraded
2Ratings
0%
-33.50%
Ironwood Pharma
Mar 21, 2016
Hold
Initiated
$14.00
(18.29% Upside)
2Ratings
100%
+7.20%
MNTA
Momenta Pharma
Jun 06, 2016
Hold
Initiated
2Ratings
0.00%
Zimmer Biomet Holdings
Apr 27, 2017
Buy
Reiterated
$138.00
(15.99% Upside)
3Ratings
50%
+4.00%
List of latest recommendations made by Gary Nachman. Click to expand and see Gary Nachman's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >